Saul Ewing Recognized As Leading Firm for ANDA Litigation

Saul Ewing Recognized As Leading Firm for ANDA Litigation
Phil. law firms among most active for new drug lawsuits
June 9, 2017
Jeff Blumenthal
Philadelphia Business Journal

Partner Charles M. Lizza, Chair of Saul Ewing’s Intellectual Property Litigation Practice and Vice Chair of the firm’s Litigation Department, is quoted in this article about courts in New Jersey and Delaware having more cases involving abbreviated new drug application (ANDA) litigation than all other federal district courts combined. The article explains that because so many pharmaceutical companies are either headquartered or incorporated in these two states, most filings have occurred there and, as a result, federal judges in New Jersey and Delaware have become experts in these sophisticated cases. The expertise of these judges, along with highly developed local patent litigation rules in New Jersey, in turn, have created predictability for lawyers such as Mr. Lizza who try these cases.

“I hate to pick on Oklahoma but would you really want to file an ANDA case there when you might get a judge who is not familiar with the technical aspects when you could file in a jurisdiction that has judges with that expertise?” Mr. Lizza said in the article.

The article also explains that Philadelphia-based law firms have benefited from this activity, including Saul Ewing, which handles more of these cases representing plaintiffs than any other firm in the city – and ranks fourth nationwide, with 146 cases since 2009. Of these cases, 95 percent stem from Saul Ewing’s Newark, New Jersey-based ANDA litigation practice overseen by Mr. Lizza.

To read the complete article, click here (subscription required).